XOMA licenses technology to Diagnostic Products:
This article was originally published in Clinica
XOMA has licensed to Diagnostic Products Corporation technology that uses lipopolysaccharide binding protein (LBP) technology which it will use to develop automated tests to detect systemic exposure to bacteria and endotoxin. Such conditions include sepsis and infectious complications of surgery and trauma. DPC has already developed automated tests for the early detection of sepsis and related infections. It claims the new technology may result in earlier diagnosis. XOMA has already licensed the LBP technology to Biosite Diagnostics to make and sell point-of-care diagnostics in the US and to SRL to make central lab tests in Japan.